In RCCs with high HMGB1 levels, bevacizumab induced a delay in tumor growth (RXF 1114, 1393, 2282, 2359 and 2395), stable disease (RXF 488, 739 and 2521) or even remission (RXF 616, 2264 and 2717). The gene discussed is HMGB1; the disease is neoplasm.